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Abstract
Introduction Patients undergoing major heart surgery (MHS)
represent a special subpopulation at risk for nosocomial
infections. Postoperative infection is the main non-cardiac
complication after MHS and has been clearly related to
increased morbidity, use of hospital resources and mortality.
Our aim was to determine the incidence, aetiology, risk factors
and outcome of ventilator-associated pneumonia (VAP) in
patients who have undergone MHS in Europe.
Methods Our study was a prospective study of patients
undergoing MHS in Europe who developed suspicion of VAP.
During a one-month period, participating units submitted a
protocol of all patients admitted to their units who had
undergone MHS.
Results Overall, 25 hospitals in eight different European
countries participated in the study. The number of patients
intervened for MHS was 986. Fifteen patients were excluded
because of protocol violations. One or more nosocomial
infections were detected in 43 (4.4%) patients. VAP was the
most frequent nosocomial infection (2.1%; 13.9 episodes per
1000 days of mechanical ventilation). The microorganisms
responsible for VAP in this study were: Enterobacteriaceae
(45%),  Pseudomonas aeruginosa (20%), methicillin-resistant
Staphylococcus aureus (10%) and a range of other
microorganisms. We identified the following significant
independent risk factors for VAP: ascending aorta surgery (odds
ratio (OR) = 6.22; 95% confidence interval (CI) = 1.69 to
22.89), number of blood units transfused (OR = 1.08 per unit
transfused; 95% CI = 1.04 to 1.13) and need for re-intervention
(OR = 6.65; 95% CI = 2.10 to 21.01). The median length of
stay in the intensive care unit was significantly longer (P  <
0.001) in patients with VAP than in patients without VAP (23
days versus 2 days). Death was significantly more frequent (P <
0.001) in patients with VAP (35% versus 2.3%).
Conclusions Patients undergoing aortic surgery and those with
complicated post-intervention courses, requiring multiple
transfusions or re-intervention, constitute a high-risk group
probably requiring more active preventive measures.
CABG: coronary artery bypass grafting; CI: confidence interval; CPB: cardiopulmonary bypass; CPIS: Clinical Pulmonary Infection Score; ESCMID: 
European Society of Clinical Microbiology and Infectious Diseases; ESGNI: European Study Group of Nosocomial Infection; EWCI: European Work-
ing Party of Cardiothoracic Intensivists; FiO2: fraction of inspired oxygen; ICU: intensive care unit; IQR: interquartile range; MHS: major heart surgery; 
NYHA: New York Heart Association; OR: odds ratio; PaO2: partial pressure of arterial oxygen; RR: relative risk; SD: standard deviation; VAP: venti-
lator-associated pneumonia.Critical Care    Vol 13 No 3    Hortal et al.
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Introduction
Patients undergoing major heart surgery (MHS) represent a
special subpopulation at risk for nosocomial infections. Post-
operative infection is the main non-cardiac complication after
MHS and has been clearly related to increased morbidity, use
of hospital resources and mortality [1,2].
Ventilator-associated pneumonia (VAP) is the most common
infection in patients admitted to intensive care units (ICUs)
[3,4] and is a leading cause of morbidity and mortality [5,6].
The situation of VAP in patients undergoing MHS has been
assessed only from the perspective of single institutions with
the bias of the case-mix at a particular centre [1,7-10]. Our
group led the collection of retrospective data of VAP in MHS
from several European institutions [11], but prospective data
from a large group of European centres were lacking.
Our study aims were to determine the incidence, aetiology,
risk factors and outcome of VAP in a large sample of patients
who have undergone MHS in Europe.
Materials and methods
Our study is a joint venture between the European Study
Group of Nosocomial Infection (ESGNI), the European Soci-
ety of Clinical Microbiology and Infectious Diseases (ESC-
MID) and the European Working Party of Cardiothoracic
Intensivists (EWCI). The Ethics Committee of Hospital Gen-
eral Universitario Gregorio Marañón (Madrid, Spain) approved
the study and indicated that individual informed consent was
not necessary in this study because no intervention was per-
formed and confidentiality was respected.
Our study (ESGNI 09 study) was a prospective (one-month
enrolment) analysis of patients undergoing MHS in Europe
who developed suspicion of VAP. During a one-month period
participating units submitted a protocol of all patients admitted
to their units who had undergone MHS. Specific variables on
VAP diagnosis and evolution were included.
Units and investigators willing to participate sent data regard-
ing the type of hospital, (public or private, teaching or non-
teaching, total population surveyed, number of beds, and the
number of hospital admissions for 24 hours or longer during
the month of the study) and data regarding the ICU used for
postoperative care of MHS patients in each institution (ICU
specific for MHS or mixed with other types of patients and
number of beds available).
Individual data for patients admitted to European postsurgical
ICUs included: hospital admission date, sex, age, prior ill-
nesses, clinical characteristics of the patient and New York
Heart Association (NYHA) functional class. Patients' underly-
ing diseases were classified according to the criteria of
McCabe and Jackson [12] as rapidly fatal, ultimately fatal and
non-fatal; their morbidity scores were based on the Charlson
co-morbidity index [13]. The American Society of Anesthesiol-
ogists physical status grading system [14] and EuroSCORE
[15] were used to value surgical risk.
Data regarding the surgical procedure included type of indica-
tion (elective, urgent or emergent), type of surgical procedure,
duration (from the skin incision until closure), time on cardiop-
ulmonary bypass, aortic cross-clamp time, surgical antimicro-
bial prophylaxis, transfusion needs, overall period with chest
drainages, number of reinterventions and need for inotropic
support, intra-aortic balloon or circulatory assistance. Surgical
prophylaxis was performed according to each centre's proto-
col.
Recorded postsurgical events included ICU admission and
discharge date, days spent on mechanical ventilation, preven-
tive methods for VAP, type of nosocomial infection and patient
evolution. If the patient had VAP, a specific part of the ques-
tionnaire was completed including criteria for diagnosis, Clini-
cal Pulmonary Infection Score (CPIS) [16], microbiological
data (microorganisms causing pneumonia) and outcome.
Definitions
VAP was diagnosed upon the presence of new and/or pro-
gressive pulmonary infiltrates on chest radiograph plus two or
more of the following criteria: fever (≥ 38.5°C) or hypothermia
(< 36°C), leucocytosis (≥ 12 × 109/L), purulent tracheobron-
chial secretions or a reduction of partial pressure of arterial
oxygen (PaO2)/fraction of inspired oxygen (FiO2) of 15% or
higher in the past 48 hours according to the definitions of the
Centers for Disease Control and Prevention [17]. Also, as
pneumonia cases we included those patients with a CPIS
higher than six [16].
Tracheobronchitis was defined as the presence of purulent
tracheobronchial secretions plus two or more of the following
criteria: fever (≥ 38.5°C) or hypothermia (< 36°C), leucocyto-
sis (≥ 12 × 109/L), or significant bacteriological counts in res-
piratory secretions in patients without pulmonary infiltrates
suggesting pneumonia on chest radiograph [17]. Cases with
either VAP or tracheobronchitis had to be microbiologically
confirmed.
The ICUs were classified as specific if more than 95% of their
beds were addressed to patients undergoing MHS or as
mixed if this criterion was not met.
Data analysis
Reports from individual centres were sent to the coordinating
centre either by regular mail or via the internet. Individual
reports were reviewed by one of the authors before being
entered into the database and analysed using SPSS Version
12 (SPSS Inc., Chicago, IL, USA).Available online http://ccforum.com/content/13/3/R80
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We expressed continuous variables as the median and inter-
quartile range (IQR) if their distribution was skewed, and dis-
crete variables as percentages. Measures of significance were
assessed by univariate and stratified analysis. Continuous var-
iables were analysed by the Mann-Whitney U test, and cate-
gorical variables were analysed with Fisher's exact test or the
chi-squared test. All statistical tests were two-tailed. The inde-
pendent contribution of predictor variables for the develop-
ment of VAP and mortality after MHS was assessed by
stepwise logistic regression analysis, and associations
between variables expressed as odds ratios (OR) and respec-
tive 95% confidence intervals (CI). As candidate variables we
included in the model all those which showed univariate signif-
icance less than P < 0.1. The aim of the study was to find pre-
operative, operative and immediate postoperative risk factors
of VAP. For this reason risk factors were analysed in two mod-
els, with and without the inclusion of the number of days of
mechanical ventilation. The models were validated by means
of the jack-knifing technique [18]. Variables which did not yield
the same results in at least 90% of the 20 jack-knifing runs
were discarded. No significant first-order interactions were
found in the models.
Results
Participating institution characteristics
Overall, 25 hospitals in eight different European countries par-
ticipated in the study (Table 1). The participating institutions
were either teaching (88%) or non-teaching hospitals (12%)
Table 1
Participating hospitals and countries
Country Hospitals Patients per hospital Patients per country
Austria AKH University Hospital 19 19
Denmark Rigshospitalet 72 72
France Albert Michallon 35 35
Italy Azienda Ospedaliera-Universita di Padova 64 64
The Netherlands Amphia Hospital 134 134
Spain Sant Creu i Sant Pau 59 487
German Trias i Pujol 19
Virgen de las Nieves 26
Clínico de San Carlos 16
Clínico Universitario de Valencia 22
Hospital Universitario 12 de Octubre 32
Hospital de Cruces 23
Mixoeiro 55
Puerta de Hierro 24
Hospital de la Princesa 23
Virgen de la Macarena 39
Gregorio Marañón 39
Clínica Ruber 13
Hospital Universitario de Canarias 20
Ruber Internacional 4
Hospital la Fe 38
Virgen de la Arrixaca 35
Sweden Sahlgrens University Hospital 69 69
Switzerland University Hospital Zurich 67 91
Centre Hospitalier Universitaire de Vaudois 24
Totals = 8 25 971Critical Care    Vol 13 No 3    Hortal et al.
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and the majority were public centres (92%). The distribution of
hospitals according to the number of beds was as follows:
less than 500 beds (16%), from 500 to 1000 beds (48%) and
more than 1000 beds (36%). Overall, these institutions had
performed 13,357 (IQR = 303 to 675) MHS procedures dur-
ing the previous year. Considering that they were responsible
for the health care of 18,173,745 people (IQR = 400,000 to
1,200,000) and they had had 996,780 admissions (IQR =
24,900 to 62,500) during the previous year, we can estimate
that there were 73.8 MHS interventions per 100,000 popula-
tion and 13.4 procedures per 1000 hospital admissions in the
areas covered by the participant institutions.
Only 44% of the ICUs surveyed were used specifically for
MHS patients and the median number of available beds in
these units was 12 (IQR = 10 to 22).
Population at risk
The number of patients intervened for MHS during the study
period in the different participating centres was 986 (Median
= 33, IQR = 21 to 58). Fifteen patients were excluded
because of protocol violations. Overall, 971 patients remained
in the study. General data regarding the population intervened
including the demographic and descriptive data of the patients
are listed in Table 2. The mean (standard deviation (SD)) age
of the patients was 64.22 (12.11) years and the median length
of in hospital preoperative stay was two days (IQR = one to
seven).
The interventions were classified as elective in 80.4% of the
patients, urgent in 15.2% and emergent in 4.3%. The antimi-
crobial prophylaxis used was cefazolin (37.8%), vancomycin
(4.6%), other drugs (57.3%) and none (0.3%). The mean
duration of surgery was 233 (96) minutes. Of the 523 patients
undergoing coronary artery bypass grafting (CABG), 122
(23.3%) were performed without cardiopulmonary bypass
(CPB). The mean CPB time was 110.1 (54.1) minutes and the
mean aortic cross-clamp time was 71.9 (42.2) minutes.
Overall, 477 patients (49.1%) were transfused and the
median number of units was three (IQR = two to six). The
patients needed inotropic support (59.1%), intra-aortic bal-
loon (6.1%) or circulatory assistance (0.5%) because of differ-
ent degrees of ventricular dysfunction. The median length of
stay in the ICU was two days (IQR = one to three).
Ventilator-associated pneumonia
Of the 971 patients undergoing MHS, 43 (4.4%) patients had
one or more nosocomial infection (Figure 1). VAP was the
most frequent nosocomial infection, with an incidence during
the study period of 2.1% (20 of 971 patients). Of these, five
patients (25%) had two VAP episodes. The incidence density
of VAP in this study was 13.9 episodes per 1000 days of
mechanical ventilation.
Overall, only 112 patients (11.5%) required more than 48
hours of mechanical ventilation and 66 (6.8%) more than 72
hours. If we consider only the patients with more than 48 hours
of mechanical ventilation, 17.9% (20 of 112) developed VAP
and the incidence reached 28.8% among those ventilated for
more than 72 hours (19 of 66). The mean CPIS of these
patients was 7.5 (1.6) points and the median number of days
on mechanical ventilation at the time of VAP was 5.5 days
(IQR = 3.0 to 7.7). VAP patients required a median number of
15 days of mechanical ventilation (IQR = 6.2 to 29.7).
In our study, seven patients (0.7%) fulfilled criteria for trache-
obronchitis at any time during their clinical course. The inci-
dence rate of tracheobronchitis was 3.7 per 1000 days of
mechanical ventilation. If we consider only the patients with
more than 72 hours of mechanical ventilation, 10.6% (7 of 66)
developed tracheobronchitis. Of these seven patients, two
developed a VAP later on. The mean CPIS of the patients with
tracheobronchitis was 5.0 (1.7) points and the median number
of days on mechanical ventilation at the time of tracheobron-
chitis was five days (IQR = three to six). Patients with trache-
obronchitis required mechanical ventilation during a median of
11 days (IQR = 8.0 to 25.0).
The microorganisms responsible for VAP in this study were:
Enterobacteriaceae (45%), Pseudomonas aeruginosa (20%),
methicillin-resistant Staphylococcus aureus (10%), Haemo-
philus influenzae (10%), Serratia species (10%) and a range
of other microorganisms. VAP was polymicrobial in 25% of the
episodes (5 among the 20 first cases).
Samples were obtained by means of plain endotracheal aspi-
rate (12; 60%), non-bronchoscopically-guided plugged tele-
scopic catheter (4; 20%), bronchoscopically-guided plugged
telescopic catheter (3; 15%) and bronchoscopically-guided
bronchoalveolar lavage (1; 5%).
Risk factors
We analysed preoperative, operative and immediate postoper-
ative risk factors for the development of VAP. In the univariate
analysis preoperative factors associated with VAP were (Table
3): mixed ICU (relative risk [RR] = 2.8), peripheral vascular dis-
ease (RR = 3), renal disease (RR = 7.9) and American Society
of Anesthesiologists score more than 3 (RR = 3.5). For surgi-
cal risk factors, the following were associated with VAP: need
for inotropic support (RR = 15), need for intra-aortic balloon
(RR = 5.5), ascending aorta surgery (RR = 9.7) and median
duration of surgery. For postoperative risk factors, the follow-
ing were associated with VAP: mean number of blood units
transfused, need for re-intervention (RR = 12.3) and days of
mechanical ventilation until onset of VAP.
Regarding multivariate analysis, two different models were
performed, not including or including the days on mechanical
ventilation in the model. As for the logistic regression modelAvailable online http://ccforum.com/content/13/3/R80
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Table 2
Preoperative and surgical characteristics of patients who underwent major heart surgery
Characteristic Global
Preoperative
Number of patients 971
Mean age in years (SD) 64.1 (12.2)
Sex, male/female 690/281
Underlying conditions (%)
Myocardial infarction 351 (36.1)
Congestive heart failure 125 (12.9)
Central nervous system disorder 82 (8.4)
Chronic obstructive pulmonary disease 84 (8.7)
Peripheral vascular disease 179 (18.4)
Ulcer disease 51 (5.3)
Diabetes mellitus 114 (11.7)
Renal disease 33 (3.4)
Malignant neoplasm 14 (1.4)
Liver disease 56 (5.8)
Severe pulmonary hypertension 29 (3.0)
Severe ventricular dysfunction 76 (7.9)
Previous cardiac surgery (%) 96 (9.9)
Mean Charlson comorbidity index (SD) 1.6 (1.6)
McCabe and Jackson groups (%)
1 68 (7.0)
2 689 (71.0)
3 214 (22.0)
New York Heart Association functional class (%)
I 148 (15.2)
II 290 (29.9)
III 390 (40.2)
IV 143 (14.7)
American Society of Anesthesiologists score (%)
1 0
2 10 (1.0)
3 673 (69.4)
4 279 (28.7
5 19 (1.9)
EuroSCORE (%)
Low risk (0 to 2) 213 (21.9)
Moderate risk (3 to 6) 407 (41.9)
High risk (> 6) 351 (36.1)Critical Care    Vol 13 No 3    Hortal et al.
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and considering the number of patients with VAP, only the four
variables which yielded stable results in all the runs of the jack-
knifing technique were included. With the use of multivariate
analysis (first model), we identified the following significant
independent risk factors for VAP (Table 4): ascending aorta
surgery (OR = 6.22; 95% CI = 1.69 to 22.89), number of
blood units transfused (OR = 1.08 per unit transfused; 95%
CI = 1.04 to 1.13) and need for re-intervention (OR = 6.65;
95% CI = 2.10 to 21.01). When 'number of days of mechani-
cal ventilation' was included as a covariate in a separate
model, significant independent risk factors for VAP were: need
for re-intervention (OR = 11.97; 95% CI = 2.76 to 51.81) and
days of mechanical ventilation (OR = 1.41 per day of mechan-
ical ventilation; 95% CI = 1.24 to 1.61).
Treatment
Data on antimicrobial management was available from 19 of
20 VAPs. Time elapsed from clinical diagnosis to the start of
therapy was classified as: less than 8 hours (9 of 19; 47.4%),
8 to 24 hours (9 of 19; 47.4%) and more than 48 hours (1 of
19; 5.2%). Empirical therapy consisted of one drug (12;
63.2%), two drugs (5; 26.3%) and more than two drugs (2;
10.5%). Empirical therapy was changed in 10 patients
(52.6%) due to microbiological data (five patients), absence of
clinical response (three patients) or both (two patients). Empir-
ical therapy was considered adequate in 13 patients (68.4%).
Definite therapy consisted of one drug (6; 31.6%), two drugs
(8; 42.1%) and more than two drugs (5; 26.3%).
Outcome
The median length of stay in the ICU was significantly longer
(P < 0.001) in patients with VAP than in patients without VAP
(23 vs 2 days). Overall ICU mortality in patients who under-
went MHS was 3% (29 of 971). Death was significantly more
frequent (P < 0.001) in patients with VAP (35% vs 2.3%).
With the use of multivariate analysis, we identified the follow-
ing significant independent risk factors for mortality: peripheral
vascular disease (OR = 3.35, CI = 1.46 to 7.67), intra-aortic
balloon (OR = 8.21, CI = 3.38 to 19.94) and need for re-inter-
vention (OR = 3.46, CI = 1.29 to 9.26). VAP was, as well, an
Surgical
Indication (%)
Elective 781 (80.4)
Urgent 148 (15.2)
Emergent 42 (4.3)
Type of surgery (%)
Valvular replacement 267 (27.5)
CABG 528 (54.4)
Mixed (valvular and CABG) 76 (7.8)
Heart transplantation 14 (1.4)
Aortic surgery 46 (4.7)
Other 40 (4.1)
Mean duration of surgery (minutes) (SD) 233 (96.0)
Mean cardiopulmonary bypass time (minutes) (SD) 110.1 (54.1)
Mean aortic cross-clamp time (minutes) (SD) 71.9 (42.2)
CABG = Coronary artery bypass grafting; SD = standard deviation.
Table 2 (Continued)
Preoperative and surgical characteristics of patients who underwent major heart surgery
Figure 1
Incidence of nosocomial infections among 971 patients undergoing  major heart surgery in Europe Incidence of nosocomial infections among 971 patients undergoing 
major heart surgery in Europe. BACT = bacteraemia; CRBI = catheter-
related bloodstream infection; MEDIAST = postsurgical mediastinitis; 
SWI = surgical wound infection; TB = tracheobronchitis; UTI = urinary 
tract infection; VAP = ventilator-associated pneumonia.Available online http://ccforum.com/content/13/3/R80
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independent risk factor for mortality (OR = 8.62, CI = 2.63 to
28.26).
Discussion
Our multicentre European study confirms that VAP was the
main cause of postoperative infection in patients undergoing
MHS in several European centres. Our results showed inci-
dence data between that reported from institutions with very
different case mixed.
Figures of incidence of nosocomial infections in general ICUs
vary from 9 to 37%, mostly depending on the type and severity
of illness of that population and the definitions used [19,20].
In patients undergoing MHS, figures of postoperative nosoco-
mial infections range from 9 to 45%, depending also on the
type of heart surgery performed [1,21].
VAP is the most common ICU-acquired infection both in gen-
eral and surgical ICUs [4,6], and that also holds true in
patients undergoing MHS [1,7,11,22]; however, rates are very
variable and range from 3 to 21.6% [1,7,8,10,21,23-25],
probably depending on the different case mix of the individual
reporting institutions.
According to the National Nosocomial Infections Surveillance
report of 2004, the median rate of VAP in 47 cardiothoracic
surgery ICUs was 6.3 (IQR = 2.9 to 12.6) per 1000 ventilation
days [26]; however, the proportion of patients undergoing
MHS in that population is not clear. In a previous study, several
European MHS units retrospectively estimated their incidence
of VAP which occurred in 3.8% of all patients undergoing
MHS [11]. The present study provides a prospectively col-
lected incidence rate of 2.1% (incidence density of 13.9 of
1000 ventilation days) which is lower than previous results
found in similar patients [1,7,8], although it is comparable with
those reported in other studies [9,10].
Microorganisms causing VAP vary considerably according to
the characteristics of the patients in the different ICU types,
the length of hospital stay and intubation. Common pathogens
include  P. aeruginosa,  S. aureus and  Enterobacteriaceae
[27]. There is no evidence that the microorganisms causing
VAP after MHS are substantially different [1,7,9] to those in
other types of patients in ICUs. In a paper from Kollef and col-
leagues [1], 59 of 605 MHS patients developed VAP. Entero-
bacteriaceae  (15 cases) and P. aeruginosa (9 cases)
predominated, as happened in our series. Our series also
Table 3
Risk factors for VAP in patients undergoing major heart surgery in Europe in a univariate analysis
Characteristic VAP (%)
(n = 20)
No VAP (%)
(n = 951)
Relative risk
(95% confidence interval
P value
Mixed ICU 12 (60) 330 (34.7) 2.8 (1.1 to 6.9) 0.02
Peripheral vascular disease 8 (40) 171 (18) 3.0 (1.2 to 7.5) 0.01
Renal disease 4 (20) 29 (3) 7.9 (2.5 to 25.2) 0.004
American Society of Anesthesiologists > 3 12 (60) 286 (30) 3.5 (1.4 to 8.6) 0.006
Need for inotropic support 20 (100) 554 (58.3) < 0.001
Need for intra-aortic balloon 5 (25) 54 (5.7) 5.5 (1.9 to 15.8) 0.005
Ascending aortic surgery 6 (30) 40 (4.2) 9.7 (3.5 to 26.7) 0.001
Median surgery duration in minutes (IQR) 287 (262 to 403) 210 (170 to 260) < 0.001
Mean number of blood units transfused (SD) 16.8 ± 19.5 2.1 ± 4.4 < 0.001
Need of re-intervention 9 (45) 59 (6.2) 12.3 (4.9 to 31) < 0.001
Median number of days on mechanical ventilation (IQR) 9.5 (5 to 29) 1 (1 to 1) < 0.001
ICU = intensive care unit; IQR = interquartile range; SD = standard deviation; VAP = ventilator-associated pneumonia.
Table 4
Risk factors for VAP in patients undergoing major heart surgery in Europe and a multivariate analysis
Characteristic Odds ratio 95% confidence interval P value
Ascending aortic surgery 6.22 1.69 to 22.89 0.006
Number of blood units transfused (per unit transfused) 1.08 1.04 to 1.13 < 0.001
Need for re-intervention 6.65 2.10 to 21.01 0.001Critical Care    Vol 13 No 3    Hortal et al.
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showed the potential presence of S. aureus and particularly
the risk of methicillin-resistant isolates. The proportion of pol-
ymicrobial VAP ranged from 13 to 55% in different studies
[28-30]. In our series 25% of the VAP episodes had more than
one microorganism present.
Various risk factors have been associated with the develop-
ment of VAP in patients undergoing MHS, including the dura-
tion of mechanical ventilation, need for reintubation,
transfusion needs, empirical administration of broadspectrum
antibiotics, type of surgery, age over 60 years, supine position
during the first 24 hours, history of chronic obstructive pulmo-
nary disease, NYHA score of 3 or higher and need for mechan-
ical intravascular support [1,7,8,21,23,24,31]. Some of these
factors were confirmed in our study, in particular, transfusion
needs and type of surgery. At the same time, our study under-
scores other risk factors such as the need for re-intervention
with haemorrhage or cardiac tamponade in the immediate
postoperative period. Our study was oriented to find preoper-
ative, intraoperative and immediate postoperative factors ame-
nable to intervention in the population undergoing MHS. Due
to this, we decided not to include the variable 'days of mechan-
ical ventilation' in the model because it completely overshad-
owed the importance of the other variables we specifically
wanted to address.
Because of this, we decided to include the variable 'days of
mechanical ventilation' in a separate model. After analysing
this new model, transfusion needs lost statistical significance.
Most unfortunately, the majority of the variables that signifi-
cantly predict VAP are not amenable to intervention. In our
opinion the use of anticipative or pre-emptive antimicrobial
therapy should be explored as one of the few potential inter-
ventions to avoid VAP in the high-risk population. It is known
that inadequate empirical therapy is associated with an
increase in VAP-related mortality, even if it is corrected in the
following hours. Singh and colleagues demonstrated that the
administration of three days of ciprofloxacin to patients with
suspicion of VAP had a very favourable impact on the cost and
length of antimicrobial use, and reduced the rate of superinfec-
tions and the emergence of resistance [32]. Also, the use of
oral decontamination, along with three days of cefotaxime or
ceftriaxone, has been demonstrated to have the potential ben-
efit of antimicrobial pre-emptive therapy in patients at high risk
of VAP [33,34]. Other potential preventive measures include
continuous aspiration of subglottic secretions [35] or the use
of polyurethane cuffed tubes [36].
The overall mortality rate for VAP in patients undergoing MHS
may be as high as 16 to 57% [1,7,9], but many critically ill
patients with VAP die because of their underlying disease
rather than of pneumonia. Crude mortality rate of patients with
VAP was found to be 35% in our study and attending physi-
cians attributed 13.8% of excess deaths to VAP. However, it
should be stated that because multiple comorbidities in these
patients, the attribution of mortality to VAP should always be
interpreted with caution.
Some limitations of this investigation should be mentioned.
Countries and institutions were not randomly selected among
the whole continent and the relative weight of the European
countries is not equilibrated. However, this study includes 25
centres from eight European countries and constitutes, to our
knowledge, the best data available to date to estimate the
dimension of this problem. On the other hand, the number of
patients with VAP is relatively low. However, our study popula-
tion includes almost 1000 cases and during a whole month all
patients undergoing operations were systematically included.
Conclusions
These data, representing several European institutions, sug-
gest that VAP is still the main cause of nosocomial infection
during the postoperative period following MHS. Due to the
scarcity of variables for intervention, anticipative or pre-emp-
tive antimicrobial therapy should be explored as one of the few
potential interventions to avoid VAP in the population remain-
ing under mechanical ventilation for more than 48 hours.
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